Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 247 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. May 16, 2019 Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... September 13, 2024 Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... April 22, 2020 Foodie Friday: What to do with all these zucchini? July 9, 2021 Load more HOT NEWS Time to get stratified Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant
